Quest LaboratoriesNSE:QUESTLAB -2.50%44 EV-to-EBITDA is 19.42 as of Jul. 03, 2026, which is 137% above its 10-year median of 8.18. GuruFocus rates NSE:QUESTLAB with a GF Score™ of 44/100. The stock has 7 warning signs investors should review. Among 740 Drug Manufacturers companies, Quest Laboratories ranks worse than 65.41% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Quest Laboratories's enterprise value is ₹1,483.0 Mil.
Quest Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹76.4 Mil. Therefore, Quest Laboratories's EV-to-EBITDA for today is 19.42.
The historical rank and industry rank for Quest Laboratories's EV-to-EBITDA or its related term are showing as below:
NSE:QUESTLAB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.55 Med: 8.18 Max: 40.88
Current: 19.42
During the past 6 years, the highest EV-to-EBITDA of Quest Laboratories was 40.88. The lowest was 5.55. And the median was 8.18.
NSE:QUESTLAB's EV-to-EBITDA is ranked worse than 65.41% of 740
companies
in the Drug Manufacturers industry
Industry Median: 12.955
vs NSE:QUESTLAB: 19.42
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Quest Laboratories's PE Ratio (TTM) for today is calculated as:
Quest Laboratories's share price for today is ₹93.75.
Quest Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹4.190.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Quest Laboratories's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:QUESTLAB vs LLY, JNJ, ABBV: EV-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Quest Laboratories's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest Laboratories EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Quest Laboratories's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Quest Laboratories's EV-to-EBITDA falls into.
Quest Laboratories's current Enterprise Value is ₹1,483.0 Mil.
Quest Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹76.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest Laboratories (NSE:QUESTLAB) has a EV-to-EBITDA of 19.42 as of Jul. 03, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Quest Laboratories. This is 137% above median its historical median of 8.18. Over the past decade, Quest Laboratories' EV-to-EBITDA has ranged from 5.55 to 40.88. According to the industry distribution chart, Quest Laboratories ranks #484 out of 740 companies in the Drug Manufacturers industry, placing it in the top 65.4%.
Is Quest Laboratories' EV-to-EBITDA too high?
Quest Laboratories' current EV-to-EBITDA of 19.42 is 137% above median its 10-year median of 8.18. Over the past 10 years, this metric has ranged from a low of 5.55 to a high of 40.88. The Drug Manufacturers industry median EV-to-EBITDA is 12.96. Quest Laboratories' value of 19.42 is 49.9% above this industry median. Based on the distribution chart, Quest Laboratories ranks #484 out of 740 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Quest Laboratories has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Quest Laboratories' EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Quest Laboratories ranks #484 out of 740 companies for EV-to-EBITDA. This places Quest Laboratories in the lower half of its industry. The industry median EV-to-EBITDA is 12.96. Quest Laboratories' value of 19.42 is 49.9% above this benchmark. Historically, Quest Laboratories' own EV-to-EBITDA has ranged from 5.55 to 40.88 over the past decade. While the company's 10-year median is 8.18 vs. the industry median of 12.96, Quest Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.96, based on 740 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quest Laboratories's current EV-to-EBITDA of 19.42 is 49.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Quest Laboratories. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quest Laboratories's current EV-to-EBITDA is 19.42, which is 137% above median its own 10-year median of 8.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Laboratories stock overvalued right now?
Quest Laboratories (NSE:QUESTLAB) has a current EV-to-EBITDA of 19.42. The current EV-to-EBITDA is 19.42, which is 137% above median its 10-year median of 8.18 and 49.9% above the Drug Manufacturers industry median of 12.96. Quest Laboratories' overall GF Score™ is 44/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Quest Laboratories (NSE:QUESTLAB), the current EV-to-EBITDA is 19.42 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quest Laboratories Ltd is engaged in the business of manufacturing pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. It produces various products, comprising ethical drugs, generic drugs, and over-the-counter drugs, and is also available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids, among others. The company operates in a single segment of Drugs and Chemicals.
44GF Score
Get the complete analysis for NSE:QUESTLAB
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QUESTLAB has been successfully added to your 
